Advantages | Disadvantages |
---|---|
• Obviates the need to collect HCV incidence data at baseline • Benefits countries which already have low baseline HCV incidence, as it prevents need for further reduction • Directs global efforts towards countries with high baseline HCV incidence, and thus, higher need for intervention • Sets a universal threshold below which the rate of HCV transmission can be considered negligible, independent of setting |
• Penalises countries with high baseline HCV incidence, as these would need to achieve greater reductions than if a relative target was used • Does not provide information on the past trajectory of HCV incidence |